Payer News - Archives

PGx in depression - new data and expert opinions

New data highlight favorable outcomes tied to pharmacogenomic (PGx) testing in depression, and expert opinions evolve regarding utility

Recent studies show improvement in patients with depression who received PGx testing to inform their clinician’s medication selection compared to patients who experienced usual care.

  • VA-sponsored PRIME Care Trial evaluated impact of PGx on psychiatric treatment outcomes and medication selection in U.S. veterans with depression. When prescribing could be informed by PGx, patients had 28% greater likelihood of achieving depression remission over 24 weeks compared to treatment as usual.1

  • Meta-analysis including >4,500 patients from 13 clinical trials showed that PGx arm experienced 41% greater likelihood of achieving remission compared to treatment as usual.2

Expert opinions continue to evolve.

  • PRIME Care Trial lead author Dr. David Oslin joined Science Friday discussing results and their impact on patient care in his practice.

  • Kristine Ashcraft, a leading voice in precision medicine, addressed the meta-analysis and advancements in PGx on The Beagle has Landed podcast.

Learn more about GeneSight

1. Oslin DW, et al. JAMA. 2022;328(2):151-161.

2. Brown L, et al. Clin Pharmacol Ther. 2022 Sep 16. doi: 10.1002/cpt.2748. Online ahead of print.

Myriad Genetics Second Quarter 2021 Financial Results Conference Call